NATCO launches anti-blood clot tablet Rivaroxaban in India

Natco Pharma Limited has announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots.

In a regulatory filing on Thursday, Natco Pharma said, "Natco Pharma Limited is pleased to announce the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots."

NATCO has launched RPIGAT in four strengths - 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of INR 14.0 per tablet. Rivaroxaban is currently sold by Bayer under the brand name of Xarelto, in the Indian market.

After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with NATCO's mission of affordable medicines accessible to all.

Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India and among the country's top three producers of hepatitis C drugs. Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.